Ultrastable mucoadhesive gold nanoparticles for corneal drug delivery

Increasing the corneal residence time of drugs is a current challenge in ophthalmology. Drug vectors with such properties can increase the efficiency of drugs, thereby reducing the frequency of administration, the duration of treatment, and the risk of post-surgical infection that may lead to sight loss.

The team of Prof Boisselier has developed a new ocular drug nanotechnology-based vector, in the form of ultrastable mucoadhesive gold nanoparticles onto which drugs can be encapsulated, to provide an efficient drug-vector formulation to delivering anti-inflammatory drugs, such as those prescribed after cataract surgery, to a mucoid surface such as the cornea.


  • Boisselier É, M Ouellette, V Pernet, and M Omar (2018). Ultrastable gold nanoparticles for drug delivery applications and synthesis thereof. Patent pending. Assignee: Université Laval

  • Masse F, M Ouellette, G Lamoureux, and É Boisselier (2019). Gold nanoparticles in ophthalmology. Med Res Rev 39: 302-327.

  • Masse F, P Desjardins, M Ouellette, C Couture, MM Omar, V Pernet, S Guérin and É Boisselier (2019). Synthesis of ultrastable gold nanoparticles as a new drug delivery system. Molecules 24: E2929.

  • Ouellette M, F Masse, M Lefebvre-Demers, Q Maestracci, P Grenier, R Millar, N Bertrand, M Prieto, and É Boisselier (2018). Insights into gold nanoparticles as a mucoadhesive system. Sci Rep 8: 14357.

Gso 16 621


Ultrastable mucoadhesive gold nanoparticules can efficiently deliver drugs to the cornea and significantly increase their residence time.

SOVAR and Université Laval seek a partner for co-development, licensing, or commercialization of this technology.

Available resources

The laboratory of Prof Boisselier can synthesize, functionalize, and characterize ultrastable gold nanoparticles, as well as encapsultating drugs for in vitro and in vivo studies.